{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000132","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.730256+00:00","generated_at":"2026-06-10T07:32:43.982589+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Kiora shareholders approve 1M-share equity plan increase and >20% issuance to Lincoln Park Capital","bullets":["Amendment to 2014 Equity Incentive Plan approved, adding 1,000,000 authorized shares (1,872,064 for, 612,104 against).","Issuance of >20% of outstanding common stock to Lincoln Park Capital Fund, LLC approved under Nasdaq Rule 5635(d) (2,051,285 for, 432,684 against).","Adjournment proposal approved but not needed as prior two proposals passed (1,951,845 for, 526,462 against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000132","json":"https://secwatch.observer/filing/0001372514-23-000132.json","markdown":"https://secwatch.observer/filing/0001372514-23-000132.md","text":"https://secwatch.observer/filing/0001372514-23-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000132/0001372514-23-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000132/kprx-20230927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:32:43.982589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2aed2ef365a18c1ca56870acced7e225653fa3ab","claim":"KIORA PHARMACEUTICALS INC shareholders approved Approval of an amendment to the 2014 Equity Incentive Plan to increase the maximum number of shares authorized for issuance by 1,000,000 shares and to revise the evergreen provision at the 2023-09-27 meeting.","evidence_excerpt":"Proposal 1 – Approval of Equity Incentive Plan Amendment The amendment to the Company’s 2014 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 1,000,000 shares and to revise the provision governing the maximum shares issuable under the evergreen provision was approved. The results of the election were as follows: Voted For Votes Against Votes Abstained 1,872,064 612,104 264,210","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000132/0001372514-23-000132-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-27"}],"fact_type":"shareholder_vote"},{"claim_id":"c9b8c56147cc1fc16713ec2df0a670aa13f74801","claim":"KIORA PHARMACEUTICALS INC shareholders approved Approval of the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the purchase agreement with Lincoln Park Capital Fund, LLC at the 2023-09-27 meeting.","evidence_excerpt":"Proposal 2 - Approval of the Issuance of More Than 20% of the Company’s Issued and Outstanding Common Stock Pursuant to the Company’s Purchase Agreement with Lincoln Park The approval, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC, was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained 2,051,285 432,684 264,409","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000132/0001372514-23-000132-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-27"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}